<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04462562</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH 2002-020-1099</org_study_id>
    <nct_id>NCT04462562</nct_id>
  </id_info>
  <brief_title>Quantitative US for Evaluation of Hepatic Steatosis in NAFLD</brief_title>
  <official_title>The Diagnostic Performance Assessment of Quantitative Ultrasound Imaging Indices for Differentiating Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medison</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate diagnostic performance of quantitative
      ultrasonographic parameters for the assessment of hepatic steatosis with find optimal cut-off
      values in patients with non-alcoholic fatty liver disease using magnetic resonance imaging
      proton density fat fraction (MRI-PDFF) and MR spectroscopy as the reference standard.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 3, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance (area under the ROC curve (AUC)) of quantitative US (QUS) parameters (TAI, TSI) for detection of fatty liver (MRI-PDFF 5%)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Reference standard: MRI-proton density fat fraction or MR spectroscopy value (5%)
- ROC curve analysis of each QUS parameters (TAI, TSI, EzHRI) for the detection of MRI-PDFF &gt;5% patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance (area under the ROC curve (AUC)) of QUS parameters (TAI, TSI) for detection of moderate fatty liver (MRI-PDFF 10%, 20%) ,</measure>
    <time_frame>2 weeks</time_frame>
    <description>Reference standard: MRI-PDFF or MR spectroscopy value (10%)
- ROC curve analysis of each QUS parameters (TAI, TSI, EzHRI) for the detection of MRI-PDFF &gt;10% patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of QUS parameters and MR fat fraction</measure>
    <time_frame>2 weeks</time_frame>
    <description>reference standard: MRI-PDFF or MR spectroscopy value (%)
- spearman's rank correlation of QUS parameters (TAI, TSI) values with MR fat fraction(%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-observer agreement of quantitative US parameters</measure>
    <time_frame>1 day</time_frame>
    <description>Intraclass correlation coefficient (ICC), coefficient of variation (CV) of QUS parameter values (TAI value, TSI value)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">173</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Fatty Liver, Nonalcoholic</condition>
  <arm_group>
    <arm_group_label>quantitative ultrasound imaging parameters</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>quantitative ultrasound imaging parameters
tissue attenuation imaging (TAI) parameter
tissue scatter-distribution imaging (TSI) parameter
Hepatorenal index (semi-auto, EzHRI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quantitative US (Samsung Medison, RS85A)</intervention_name>
    <description>In each patients, measurements of tissue attenuation imagine (TAI), tissue scatter-distribution imaging (TSI) parameters, hepatorenal index (EzHRI) will be performed</description>
    <arm_group_label>quantitative ultrasound imaging parameters</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with known NAFLD or suspected of having NAFLD

          -  Patients who are scheduled hepatectomy for living donor liver donation

          -  aged â‰¥ 18 years who are willing and able to complete all procedures

        Exclusion Criteria:

          -  excessive alcohol consumption within 2 years (40g/day for men, 20g/day for women)

          -  clinical, laboratory, or histologic evidence of a liver disease other than NAFLD,
             including viral hepatitis, autoimmune hepatitis, or genetic or acquired disorders

          -  use of steatogenic or hepatotoxic medication

          -  evidence of decompensated liver disease

          -  history of liver surgery

          -  contraindication to MRI

          -  any other condition believed by investigator to affect a patients' compliance, or
             completion of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun Kyung Jeon, MD</last_name>
    <phone>82-2-2072-3107</phone>
    <email>sunkyung417@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>July 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

